ATF6 is one of three sentinels of the unfolded protein response, a cellular quality-control system that monitors the endoplasmic reticulum, the organelle where newly made proteins fold into their functional shapes. Its two counterparts, PERK and IRE1α, respond to an accumulation of misfolded proteins by throttling back protein synthesis and degrading faulty transcripts. ATF6 takes a different route: under stress it travels from the endoplasmic reticulum to the Golgi apparatus, where enzymes known as site-1 and site-2 protease cleave it into an active fragment called ATF6p50. This fragment then enters the nucleus and switches on genes encoding molecular chaperones, including BiP and Grp94, which boost the cell’s protein-folding capacity and help restore order in the endoplasmic reticulum. Far from being a mere emergency brake, ATF6 has emerged in recent years as an active defender of endothelial barriers, the tight cellular linings that control what passes into and out of tissues, and it also displays pronounced anti-inflammatory activity.

The research team, led by investigators at the University of Louisiana Monroe’s College of Pharmacy, asked a specific question: does ATF6 mediate the beneficial effects of growth hormone-releasing hormone antagonists, a family of synthetic peptides known for their anti-inflammatory and cytoprotective properties across many tissues, in corneal endothelial cells? Earlier work from the same group had shown that one such antagonist, JV-1-36, shields endothelial corneal cells from inflammation triggered by lipopolysaccharide, a bacterial toxin. JV-1-36 treatment reduced endothelial hyperpermeability, dampened the generation of reactive oxygen species, suppressed inflammatory signaling through the MAPK and STAT pathways, and lowered the production of pro-inflammatory cytokines. But the mechanism connecting the drug to those outcomes remained incomplete, and the unfolded protein response had already been implicated in the endothelial effects of these antagonists in lung models, both in cultured cells and in living animals.

To manipulate ATF6 pharmacologically, the team used two well-characterized small molecules that act on opposite ends of the pathway. AA147 promotes ATF6 activation, while Ceapin-A7 blocks it. Before drawing any conclusions about barrier function, the researchers first verified that neither compound was toxic to the bovine corneal endothelial cells they were studying, a line known as BCE C/D-1b. Using the MTT assay, which measures the metabolic activity of living cells, they found that both AA147, tested across a range of 1 to 200 micromolar, and Ceapin-A7, tested from 1 to 100 micromolar, left cell viability untouched between 1 and 25 micromolar. That safety window allowed the team to probe ATF6 signaling without the confounding effect of cell death, an essential control in studies of barrier integrity where membrane damage could masquerade as permeability changes.

The next step was to confirm that the two modulators genuinely moved the ATF6 needle. Western blot analysis of protein expression showed that AA147 increased the abundance of Grp94 and BiP, both canonical downstream targets of the activated transcription factor, in a manner that varied with dose and exposure time across 8, 16, and 24 hours. Ceapin-A7 did the opposite, suppressing the expression of both chaperones and thereby demonstrating that ATF6 signaling had been effectively silenced. These complementary results established a clean pharmacological system: one drug to turn the pathway up, another to turn it down, with two protein readouts to verify that the dial was actually moving. It is the kind of rigor that distinguishes pathway studies from simple drug-response experiments.

With the toolkit validated, the team turned to the central functional question. Barrier integrity was assessed with a fluorescein isothiocyanate dextran permeability assay, in which a 70-kilodalton fluorescent tracer is added to the top of a transwell culture insert and its passage through the cell monolayer is quantified by fluorescence measurement. When cells were pretreated with AA147 and then exposed to the growth hormone-releasing hormone antagonist, paracellular permeability dropped further than with either compound alone, indicating that activating ATF6 amplified the barrier-protective effect of the peptide. Conversely, pretreatment with Ceapin-A7 undermined the antagonist’s protection, and permeability rose significantly compared with cells receiving the antagonist alone. In other words, the same drug could be made more effective or less effective simply by dialing ATF6 up or down.

Oxidative stress told the same story from a different angle. Reactive oxygen species were measured with a dichlorofluorescein diacetate probe, which fluoresces upon oxidation inside living cells. Both the ATF6 activator and the growth hormone-releasing hormone antagonist reduced ROS generation on their own, and combined ATF6 activation with antagonist treatment produced a larger decline in ROS than either intervention by itself. When ATF6 was inhibited with Ceapin-A7, the antioxidant benefit of the antagonist was blunted and ROS levels climbed. This matters because excessive ROS is a major driver of endothelial dysfunction: it promotes cytoskeletal contraction, disrupts intercellular junctions, and activates redox-sensitive inflammatory signaling cascades such as NF-κB and MAPK. Moreover, oxidative stress and endoplasmic reticulum stress feed each other in a vicious loop, with impaired protein folding fueling further oxidant production and vice versa, accelerating barrier breakdown.

The clinical context gives these cellular findings their urgency. Corneal endothelial cell density is roughly 3,000 to 4,000 cells per square millimeter in newborns and declines by about 0.6 percent per year, falling to around 2,500 in adulthood and 2,000 in old age. Fuchs dystrophy, intraocular surgery, and inflammatory conditions such as keratitis accelerate that loss. Keratitis, whether caused by bacteria, viruses, fungi, or parasites, remains a leading cause of corneal morbidity worldwide, and contact lens wear is a prominent risk factor through microtrauma, hypoxia, and lapses in hygiene that invite microbial colonization. Once pathogen-associated molecular patterns engage the innate immune machinery of corneal endothelial cells, inflammatory pathways fire, junctions loosen, the stroma swells, and clarity fades. Current pharmacological options, including antibiotics, antivirals, antifungals, corticosteroids, and nonsteroidal anti-inflammatory drugs, can control infection and inflammation but carry real drawbacks, from secondary infections and delayed wound healing to elevated intraocular pressure. Therapies that restore barrier stability while sidestepping those side effects are badly needed.

That is where the therapeutic logic of this study becomes compelling. Growth hormone-releasing hormone antagonists have previously been shown to alleviate experimental ocular inflammation and to induce apoptosis selectively in retinoblastoma cells, and the present work demonstrates for the first time that ATF6 participates, at least in part, in mediating their protective effects on corneal endothelial paracellular permeability. The authors note an interesting wrinkle: somatostatin analogs, several of which are already FDA-approved, have been reported to activate ATF6, though they are not targeted ATF6 activators. That raises the possibility that existing drugs could be repurposed to engage this pathway while more selective ATF6 modulators are developed. The finding also echoes earlier work showing that ATF6 inhibition suppresses the barrier-protective effects of somatostatin analogs such as octreotide and pasireotide in other endothelial contexts, suggesting ATF6 may be a common final mediator of peptide-driven endothelial protection.

Important caveats remain before this science can reach the clinic. The experiments were performed in bovine corneal endothelial cells, and the team plans to validate the findings in human corneal endothelial cells and in rabbit models of corneal dysfunction, while also directly measuring ATF6 cleavage to reinforce pathway specificity. Off-target effects must be examined as well, particularly any impact on the other unfolded protein response branches, PERK and IRE1α, since those pathways also influence barrier function. Still, the core message is striking: a single stress-sensing transcription factor helps determine whether a protective peptide can keep the cornea’s delicate pump-leak machinery intact. If pharmacological activation of ATF6 can be harnessed safely, it could open a new front against inflammatory corneal disease, offering hope to the millions whose sight depends on the quiet, tireless work of a monolayer of cells most people never think about until it fails.

Subject of Research: The role of the unfolded protein response sensor ATF6 in mediating the protective effects of growth hormone-releasing hormone antagonists in the corneal endothelium

Article Title: Activating transcription factor 6 is involved in the beneficial effects of growth hormone-releasing hormone antagonists in the corneal endothelium

Article References: Activating transcription factor 6 is involved in the beneficial effects of growth hormone-releasing hormone antagonists in the corneal endothelium. (n.d.). https://doi.org/10.3389/fopht.2026.1946815

Image Credits: AI Generated

DOI: 10.3389/fopht.2026.1946815

Keywords: corneal endothelium, ATF6, unfolded protein response, GHRH antagonists, barrier integrity, reactive oxygen species, keratitis, endoplasmic reticulum stress, BiP, Grp94, ocular inflammation, drug repurposing